851 results about "Heterocyclic compound" patented technology

A compound, as shown in Formula I, is a multi-heterocyclic compound. It has been verified that the compound provided by this invention integrates a novel compound targeting the calcitonin gene-related peptide (CGRP) based on ephedrine. Upon contact with the skin, due to photoactivated cell biological function regulation and the blocking effect of the multi-heterocyclic compound I structure on serotonin receptors, it achieves therapeutic effects on cutaneous vascular malformations and telangiectasia, improves the effectiveness of phototherapy in improving chronic cutaneous vascular diseases, and promotes skin wound healing.

Disclosed in the present invention is a novel substituted heterocyclic compound having VAV1 target degradation activity. Specifically disclosed is a compound serving as a VAV1 target degradation agent and having the structure of formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, isotopic substituent or isomer of the compound. The compound can be used for preventing or treating diseases related to VAV1 targets or signaling pathways.

Provided herein are certain compounds and imaging agents useful for detecting a disease or condition associated with protein aggregation, compositions thereof, and methods of their use.

A method for producing an aromatic heterocycle-substituted difluoroacetic acid derivative having a partial structure represented by the formula (III), by reacting an N-oxido aromatic heterocyclic compound having a partial structure represented by the formula (I) with tetrafluoroethylene in the presence of a compound represented by the formula (II): R—YH, in a solvent selected from an aromatic hydrocarbon solvent, an ester solvent and an ether solvent:

The invention discloses a dual-band acridine formic acid anthracene methyl ester photocatalyst as well as a preparation method and application thereof, and belongs to the field of heterocyclic compounds. The invention designs and synthesizes a novel acridine formic acid anthracene methyl ester photocatalyst, which has good compatibility in two wavebands of 365 nm and 405 nm, can realize photocatalysis of disulfide compounds and aryl formyl peroxide compounds, and provides a new thought for preparation of sulfoxide compounds with asymmetric structures; the reaction conditions are mild, the reaction time is short, the photocatalyst can be recycled, the circulation loss is low, the circulation efficiency is high, the production efficiency is greatly improved, and the production period and cost are reduced; the product is free of transition metal residues and high in yield.

The invention provides novel bicyclic heteroaryl and heterocyclic compounds and derivatives that inhibit Werner Syndrome ATP dependent helicase enzyme (WRN) activity. The invention also provides pharmaceutical compositions comprising compounds of the invention and methods thereof for treating various diseases and disorders associated with or related to WRN activity, such as various types of cancer.

The invention relates to a porous aromatic ion framework material as well as a preparation method and application thereof in iodine adsorption. The structural formula is shown as a formula (I) or a formula (II), an organic monomer with electronegativity and a triazine nitrogen-containing heterocyclic compound are adopted as construction elements, the porous aromatic ion framework material is prepared through Friedel-Crafts alkylation reaction self-polymerization or copolymerization, and tedious steps such as post-modification are avoided. A large number of benzene rings exist in the polymer, an ion skeleton provides rich active sites, and the material can rapidly adsorb steam iodine and iodine elementary substances in a solution in a large amount. The porous aromatic ion framework material prepared by the invention has excellent stability, can be used as a novel solid adsorbent to capture elemental iodine from a severe environment, is easy to recover, can be recycled, and has a good application prospect in the practical application of iodine capture.

The invention discloses a dual-band dianthracene photocatalyst as well as a preparation method and application thereof, and belongs to the field of heterocyclic compounds. The novel 2, 9 '-dianthracene photocatalyst is designed and synthesized, the compatibility at the two wavebands of 365 nm and 405 nm is good, the tetrahydroisoquinoline phosphoramidite can be induced by light, and a new thought is provided for preparing an alpha-phosphoramidate compound; the reaction conditions are mild, the reaction time is short, the photocatalyst can be recycled, the circulation loss is low, the circulation efficiency is high, the production efficiency is greatly improved, and the production period and cost are reduced; the product is free of transition metal residues and high in yield.

The invention relates to the field of medicine, and discloses a heterocyclic compound with a GLP-1 receptor agonist effect and application of the heterocyclic compound, the heterocyclic compound is a compound with a structure shown in a formula (I), or an isomer, an isotope labeled compound, a prodrug, or pharmaceutically acceptable salt, ester, hydrate or solvate of the compound. The obvious treatment effect is realized in the aspect of reducing blood sugar or reducing weight.

The present invention aims to provide novel compounds and their salts that are effective in the treatment, prevention, and / or diagnosis of seizures in diseases accompanied by epileptic seizures or convulsive seizures. [Solution] Formula I: TIFF2026050464000087.tif2685 [In the formula, each symbol is as described in the specification.] This relates to the pharmaceutical uses of the compounds and salts thereof shown in [reference]. These compounds and salts are useful for the treatment, prevention, and / or diagnosis of seizures in diseases involving epileptic or convulsive seizures (including multidrug-resistant seizures, refractory seizures, acute symptomatic seizures, febrile seizures, and status epilepticus).

The present invention relates to the field of medicines and relates to a fused five-membered and six-membered heterocyclic compound, a preparation method therefor, and a use thereof in the field of pharmaceuticals. Specifically, the present invention provides a compound having a structure represented by formula (I), or a stereoisomer, a tautomer, a solvate, a metabolite, a pharmaceutically acceptable salt, or a prodrug thereof. The compound and a pharmaceutical composition thereof of the present invention can be used for preparing a medicament for treating HIF-2α-mediated related diseases, such as renal anemia, chronic kidney disease, chronic metabolic disease, neurodegenerative disease, infection, inflammatory disease, pulmonary edema, and acute respiratory distress syndrome.

Provided are a heterocyclic compound, an organic light-emitting device including the heterocyclic compound, and an electronic device including the organic light-emitting device, the heterocyclic compound being represented by Formula 1 and Formula 2, wherein, in Formula 1 and Formula 2, each group and parameter can be understood by referring to the detailed description.

The present invention relates to novel compounds of Formula (I), wherein P, Q, A, B, m, n, R1, Z, J and L are defined as in Formula (I); which are gamma-(y)-aminobutyric acid type B receptor ("GABAB-R") positive allosteric modulators which are useful for the treatment or prevention of neurological and psychiatric disorders associated with GABA dysfunction and diseases in which the GABAB receptor is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes of preparing such compounds and such compositions, and to the use of such compounds for the prevention or treatment of neurological and psychiatric disorders and diseases in which GABAB-R is involved.

Disclosed in the present invention are a heterocyclic compound, a pharmaceutical composition, and a use of the heterocyclic compound or the pharmaceutical composition. Provided is a heterocyclic compound, or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorphic substance, solvate, isotope derivative, or prodrug thereof. The heterocyclic compound has a structure represented by formula (I). The heterocyclic compound provided in the present invention has inhibitory activity against a TEAD protein, can effectively inhibit the interaction between TEAD and YAP, and thus can treat diseases related to abnormal regulation of the TEAD protein or an abnormal Hippo pathway.

Provided is a compound useful as an active ingredient in a pharmaceutical composition for treating cancer.　The present inventors have examined a compound useful as an active ingredient in a pharmaceutical composition for cancer treatment, and have completed the present invention by finding that: a heterocyclic compound represented by formula (I) and formula (I-I) has excellent an action of inducing degradation of a mutant KRAS protein and a wild-type KRAS protein, and in particular, an action of inducing degradation of a KRAS protein having a G12C mutation, G12D mutation, G12V mutation, or G13D mutation; and said heterocyclic compound has mutant KRAS inhibition and the inhibitory activity of KRAS amplified by a wild-type KRAS gene, and in particular, inhibitory activity of KRAS having a G12C mutation, G12D mutation, G12V mutation, or G13D mutation. The heterocyclic compound according to the present invention or a salt thereof can be used as a therapeutic agent for cancer.

The application discloses an electrolyte, a preparation method thereof and a lithium ion battery, and belongs to the technical field of batteries.The electrolyte comprises a lithium salt, a first additive, a second additive and a solvent; the first additive is a compound carrying an isocyanate substituent and a nitrile substituent in a molecular structure; and the second additive is a sulfur-containing heterocyclic compound.The first additive of the electrolyte can remove water and HF in the electrolyte, prevents HF from attacking CEI and causing transition metal dissolution of a ternary positive electrode material and destruction of a material structure; the nitrile substituent has extremely strong complexing force with transition metals, inhibits electrolyte oxidative decomposition and positive electrode transition metal element dissolution; the second additive has the advantages of impedance reduction and gas production inhibition but is prone to generating acidic substances; the first additive has water and acid removal functions and can inhibit the second additive from generating acidic substances; and the synergistic effect of the two additives can improve the compatibility of the electrolyte and the ternary positive electrode material and improve the electrochemical performance of the lithium ion battery.

The application discloses a five-heterocycle compound, a preparation method and application thereof. Specifically disclosed are a compound as shown in formula I, a pharmaceutically acceptable salt or solvate thereof, a composition containing the compound, and a pharmaceutical use of the compound for preparing a drug for treating a disease or disorder related to the mechanism of action of KRAS G12C mutant protein. The five-heterocycle compound in the application has the activity of inhibiting the proliferation of Ba / F3 KRAS-G12C cells, NCI-H358 cells and MIA PaCa-2 cells expressing KRAS G12C mutant protein, and has a good inhibitory effect on the growth of a subcutaneous transplanted tumor of a NCI-H358 nude mouse.

A heterocyclic compound represented by Formula 1, an organic light-emitting device including the heterocyclic compound, and an electronic apparatus:wherein, in Formula 1,Cz1 is a group represented by Formula 2,k1 to k3 are each independently 0, 1, 2, 3, 4, or 5, and a sum of k1 to k3 is 1 or greater,and wherein the descriptions of the remaining substituents in Formula 1 and Formula 2 are as provided herein.

The invention relates to a method for synthesizing an iodo-pyridine compound from N-propargyl enaminone, which comprises the following steps: by taking N-propargyl enaminone as a raw material, DMF (Dimethyl Formamide) as a reaction solvent and copper acetate and N-iodosuccinimide as accelerators, carrying out intramolecular coupling reaction at 60 DEG C to synthesize the iodo-pyridine compound. The method for directly synthesizing the pyridine heterocyclic compound through the intramolecular coupling reaction of the N-propargyl enaminone under the non-alkaline condition is disclosed for the first time, reaction substrates are not limited to benzene rings on alkynyl, the application range of the reaction is greatly expanded, and the method has the advantages of being wide in substrate range, strong in functional group application range, mild in reaction condition, easy to operate, safe, high in yield and the like. And raw materials are cheap.

Disclosed are an organic light emitting device including a first heterocyclic compound to a third heterocyclic compound, a composition for an organic material layer of an organic light emitting device, and a method for manufacturing an organic light emitting device. The organic light emitting device and the composition for an organic material layer thereof according to an exemplary embodiment of the present application can not only lower the driving voltage of the device and improve the light efficiency, but also improve the thermal stability of the compound, thereby improving the service life characteristics of the device.

The present specification relates to a heterocyclic compound represented by Chemical Formula 1, and an organic light emitting device including the same.

A novel aryl ether substituted heterocyclic compound has GLP1R agonist activity. A GLP1R agonist is represented by formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, isotope substituent or isomer thereof.

The application discloses a preparation method of a nitrogen-containing heterocyclic compound and an alkali metal salt of the nitrogen-containing heterocyclic compound, and steps of the preparation method of the nitrogen-containing heterocyclic compound comprise: (1) uniformly mixing trithiocyanic acid with a first solvent, introducing sulfuryl fluoride gas or adding an alkenyl sulfonyl fluoride to perform a reaction, and obtaining a crude product through a crude treatment after the reaction is finished; (2) purifying the crude product to obtain the nitrogen-containing heterocyclic compound shown in a structural formula 1; wherein R1, R2 and R3 are each independently selected from -H, -SO2F or -CH2-(CH2) n -SO2F, n is an integer selected from 1-10, and R1, R2 and R3 are not H at the same time. The preparation method of the nitrogen-containing heterocyclic compound and the alkali metal salt of the nitrogen-containing heterocyclic compound can be applied to a large amount of trithiocyanic acid in a lithium battery electrolyte, raw materials are easy to obtain, operation is simple, the yield is high, the condition is mild, the requirement for equipment is low, and the method is suitable for industrial production.

The invention belongs to the technical field of chemical prevention and control of agricultural diseases and insect pests, and provides an antiviral heterocyclic compound. The heterocyclic compound has a relatively good inhibition effect on plant viruses, has passivation, protection and treatment effects after being applied to plants, is superior to a commercial medicament virazole, has good biological activity and has a commercial prospect; the invention also provides a composition containing the heterocyclic compound. When the composition contains ningnanmycin, the two components have a remarkable synergistic effect in a certain proportion range, and the resistance risk of a single agent can be reduced. The invention provides a new medicament for preventing and treating plant viruses, and has important practical application value.

The invention discloses a phenoxazine skeleton-containing drug small molecule and application thereof, and belongs to the technical field of synthesis of heterocyclic compounds and antitumor drugs, the phenoxazine skeleton-containing drug small molecule has an inhibition effect on HepG2 and A549, a phenoxazine derivative 7c with the third site connected with a methoxy group at the tail end of a phenoxazine structure benzene ring has a better overall effect, and the phenoxazine skeleton-containing drug small molecule can be applied to preparation of antitumor drugs. The inhibition rates of the compound on HepG2 and A549 are respectively 87.67% and 94.23%. 7g of the phenoxazine derivative of which the methyl ester structure is connected to the third site of the phenoxazine structure only has an obvious effect on A549, and the inhibition rate in A549 cells is 96.00%.

To provide a substituted heterocyclic fused cyclic compound having a novel structure, which is used as a selective inhibitor for KRAS mutations and has the advantages of high activity, good selectivity, low toxicity and side effects, etc.SOLUTION: The present invention relates to a substituted heterocyclic fused cyclic compound as represented by formula (I) or formula (IA) and having a selective inhibitory effect on KRAS gene mutation, or a pharmaceutically-acceptable salt, a stereoisomer, a solvate or a prodrug thereof, a pharmaceutical composition containing the compound, and an application thereof to the preparation of cancer drugs.SELECTED DRAWING: None

The invention relates to a preparation containing a heterocyclic compound or a compound formed by the heterocyclic compound and pharmaceutically acceptable salt as well as a preparation method and application of the preparation. The preparation comprises an active component and a pharmaceutically acceptable carrier, the content of the active component is 1 wt%-50 wt%; the active component is a compound as shown in a formula I-3B or a compound thereof; the compound of the compound as shown in the formula I-3B is a compound formed by the compound as shown in the formula I-3B and pharmaceutically acceptable acid. The application comprises the following steps: preparing a 15-PGDH inhibitor, and / or preparing a medicine, a pharmaceutical composition or a preparation for preventing and / or treating 15-PGDH related diseases. .

The invention discloses a nitrogen-containing heterocyclic compound and an organic electroluminescent device thereof, and relates to the technical field of organic electroluminescent devices. The nitrogen-containing heterocyclic compound provided by the invention has an appropriate energy level structure, excellent charge transfer performance and good thermal stability and chemical stability. When the material is used as a main material of a light-emitting layer of an OLED device, a carrier injection barrier between the light-emitting layer and an adjacent functional layer can be effectively reduced, meanwhile, the driving voltage of the device can be effectively optimized, the light-emitting efficiency is improved, and the service life is prolonged.